Related Experiment Videos
[Guidelines for respiratory syncytial virus prophylaxis. An update]
X Carbonell-Estrany1, J Quero Jiménez
1Instituto Clínico de Ginecología, Obstetricia y Neonatología, Unidad Integrada de Pediatría, Hospital Clínic, Barcelona, Spain. xcarbo@clinic.ub.es
Insights
Hospitalization rates for respiratory syncytial virus (RSV) in premature infants remain high, with significant ICU admissions. Current prophylaxis guidelines for RSV in preterm infants are still supported by available data on palivizumab efficacy and safety.
Area of Science:
- Pediatric Infectious Diseases
- Epidemiology
- Neonatology
Context:
- Respiratory syncytial virus (RSV) poses a significant health risk to premature infants.
- Recent epidemiological data from the IRIS study group highlight substantial hospitalization and intensive care unit (ICU) admission rates for RSV in preterm infants.
Purpose:
- To assess the current burden of RSV hospitalizations in premature infants.
- To evaluate the continued relevance of existing prophylaxis guidelines in light of recent epidemiological findings and treatment options.
Summary:
- Epidemiological studies over two RSV seasons indicated hospitalization rates of 13.4% and 13.1% for premature infants born before or at 32 weeks gestation.
- A notable percentage of these hospitalized infants (18% and 25%) required intensive care unit admission.
- Current data support the efficacy and safety of RSV monoclonal antibodies, such as palivizumab, with no evidence necessitating changes to the 2000 prophylaxis guidelines for preterm infants.
Impact:
- Reinforces the need for continued vigilance and effective preventive strategies against RSV in vulnerable preterm populations.
- Provides evidence supporting the current recommendations for RSV prophylaxis in premature infants.
- Highlights the ongoing importance of palivizumab in managing RSV risk in high-risk infants.
Abstract:
Epidemiological studies performed by the IRIS study group in the last two respiratory syncytial virus (RSV) seasons found that the hospitalization rates for RSV in premature infants born before or in week 32 of gestation were 13.4 % and 13.1 %, respectively. Of these, 18 % and 25 % of the infants were admitted to the intensive care unit. Currently available information demonstrates the efficacy of RSV monoclonal antibodies (palivizumab) and the absence of major adverse effects. To date, there are no data that indicate the need to modify the guidelines for RSV prophylaxis in premature infants published in 2000.